{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:58:18Z","timestamp":1778821098944,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jchromb.2024.124105","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T17:30:26Z","timestamp":1711387826000},"page":"124105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["LC-MS\/MS methods for simultaneous determination of youkenafil and its metabolite M1 in human seminal plasma and plasma: Application to evaluate the acute effect of youkenafil on semen quality and its pharmacokinetics in human"],"prefix":"10.1016","volume":"1237","author":[{"given":"Keli","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengwen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juefang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-0985","authenticated-orcid":false,"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124105_b0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2023.2242768","article-title":"Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments","volume":"32","author":"Melchiode","year":"2023","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.jchromb.2024.124105_b0010","doi-asserted-by":"crossref","first-page":"1123383","DOI":"10.3389\/fendo.2023.1123383","article-title":"Erectile dysfunction and exosome therapy","volume":"14","author":"Feng","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jchromb.2024.124105_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pop.2019.02.006","article-title":"Erectile dysfunction","volume":"46","author":"Irwin","year":"2019","journal-title":"Prim. Care"},{"key":"10.1016\/j.jchromb.2024.124105_b0020","first-page":"qead040","article-title":"Stem cell therapy for erectile dysfunction: a systematic review","author":"Furtado","year":"2023","journal-title":"Sex Med. Rev."},{"key":"10.1016\/j.jchromb.2024.124105_b0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clinthera.2017.01.001","article-title":"Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation","volume":"39","author":"Scaglione","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jchromb.2024.124105_b0030","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2174\/0929867327666200923151924","article-title":"Repurposing of the PDE5 inhibitor sildenafil for the treatment of persistent pulmonary hypertension in neonates","volume":"28","author":"Poitras","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jchromb.2024.124105_b0035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-pharmtox-040122-034745","article-title":"Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders","volume":"63","author":"Samidurai","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jchromb.2024.124105_b0040","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/cpdd.1108","article-title":"Safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of youkenafil hydrochloride, a phosphodiesterase type 5 inhibitor, in healthy chinese male volunteers","volume":"11","author":"Liang","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jchromb.2024.124105_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106213","article-title":"Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects","volume":"175","author":"Wang","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.jchromb.2024.124105_b0050","first-page":"53S","article-title":"The effects of sildenafil on human sperm function in healthy volunteers","volume":"53","author":"Purvis","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124105_b0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpba.2013.01.019","article-title":"Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography\/tandem mass spectrometry","volume":"77","author":"Ma","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124105_b0060","unstructured":"U.S. Food and Drug Administration, Center for drug evaluation and research, Avanafil Medical Review(s), 2011. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202276Orig1s000MedR.pdf>."},{"key":"10.1016\/j.jchromb.2024.124105_b0065","doi-asserted-by":"crossref","first-page":"e5606","DOI":"10.1002\/bmc.5606","article-title":"Development and validation of LC-MS\/MS methods for the simultaneous quantification of sofosbuvir and its major metabolite (GS-331007) in blood plasma and cerebrospinal and seminal fluid: application to a pilot clinical trial with a focus on Zika","volume":"37","author":"Vilhena","year":"2023","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2024.124105_b0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.talanta.2015.03.013","article-title":"Development and validation of LC-MS\/MS method for quantification of bisphenol A and estrogens in human plasma and seminal fluid","volume":"140","author":"Vitku","year":"2015","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2024.124105_b0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2016.08.011","article-title":"Development and validation of a LC-MS\/MS method for the quantification of tenofovir and emtricitabine in seminal plasma","volume":"1033\u20131034","author":"Illamola","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124105_b0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpba.2008.04.004","article-title":"A rapid and sensitive LC-MS\/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies","volume":"47","author":"Wang","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124105_b0085","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1002\/jssc.201600445","article-title":"Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma","volume":"39","author":"Sun","year":"2016","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jchromb.2024.124105_b0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchromb.2018.02.025","article-title":"Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography-tandem mass spectrometry","volume":"1081\u20131082","author":"He","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124105_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123723","article-title":"Development and validation of LC-MS\/MS methods for the determination of EVT201 and its five metabolites in human urine: application to a mass balance study","volume":"1223","author":"Liu","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124105_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123906","article-title":"LC-MS\/MS method for quantitative profiling of ketone bodies, \u03b1-keto acids, lactate, pyruvate and their stable isotopically labelled tracers in human plasma: an analytical panel for clinical metabolic kinetics and interactions","volume":"1230","author":"Afshar","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124105_b0105","unstructured":"U.S. Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry, 2018. <https:\/\/www.fda.gov\/media\/70858\/download>."},{"key":"10.1016\/j.jchromb.2024.124105_b0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.jchromb.2024.124105_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.115964","article-title":"Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201): application to its dose-escalation pharmacokinetic study","volume":"240","author":"Li","year":"2024","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T19:19:46Z","timestamp":1712690386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":23,"alternative-id":["S1570023224001132"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124105","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS methods for simultaneous determination of youkenafil and its metabolite M1 in human seminal plasma and plasma: Application to evaluate the acute effect of youkenafil on semen quality and its pharmacokinetics in human","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"124105"}}